varicella zoster virus glycoprotein E
varicella zoster virus glycoprotein E: 3 clinical trials tracked.
varicella zoster virus glycoprotein E evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about varicella zoster virus glycoprotein E, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 2 study sponsors
Related indications
No linked indication is available.
Clinical Trial Registry Records (3)
A Phase 1/2 Randomized, Observer-Blinded, Active-Controlled, Dose, Escalation Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Participants 50 Years of Age and Over
Primary endpoint: Part 1 and Part 2: Percentage of participants with solicited local and systemic post-injection reactions (PIRs)
A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS
Primary endpoint: SSA: Percentage of participants reporting local reactions
A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults ≥50 Years of Age
Primary endpoint: Number Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions